AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23335369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunohistochemical or FISH/immunohistochemical score
Number of subjects: 442
Study 21569539 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 112
Study 21569539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 112
Study 21569539 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-epileptic drugs)
Number of subjects: 112
Study 19229428 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 101
Study 19229428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 16543098 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal morphine (0.2 mg)
Number of subjects: 30
Study 16543098 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (Control)
Number of subjects: 30
Study 14597934 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy for CHF
Number of subjects: 6
Study 14597934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10912311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 10912311 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal and hormonal agents
Number of subjects: 0
Study 9238869 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Interclean (ID2)
Number of subjects: 48
Study 9238869 — intervention group
Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 48
Study 1740203 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona drilling procedure
Number of subjects: 20
Study 1740203 — intervention group
Group type: COMPARATOR
Intervention: Control oocytes
Number of subjects: 20
Study 6144266 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 20
Study 6144266 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 20
Study 6144266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine after furosemide
Number of subjects: 20
Study 6144266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 20
Study 6144266 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 30656454 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple curriculum including theoretical and practical training for laparoscopic salpingectomy.
Number of subjects: 20
Study 30656454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 20
Study 29867230 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 305
Study 29867230 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (monotherapy)
Number of subjects: 305
Study 29867230 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 305
Study 25990196 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration (FMV) treatment according to the 'repeated muscle vibration' protocol
Number of subjects: 50
Study 25990196 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 50
Study 23440143 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise and nutritional guidance program (3 times a week for 12 weeks)
Number of subjects: 44
Study 23440143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 22074834 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II Division 1 malocclusion (CL2 group)
Number of subjects: 120
Study 22074834 — intervention group
Group type: COMPARATOR
Intervention: Class I normal occlusion (CL1 group)
Number of subjects: 120
Study 19058081 — intervention group
Group type: EXPERIMENTAL
Intervention: Helix aspersa extract cream applied twice daily for a maximum period of 14 days or until full epithelialization
Number of subjects: 27
Study 19058081 — intervention group
Group type: COMPARATOR
Intervention: Moist exposure burn ointment (MEBO)
Number of subjects: 27
Study 17365757 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling intervention
Number of subjects: 1058
Study 15643550 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE-018 with a high-fat meal (treatment B)
Number of subjects: 0
Study 15643550 — intervention group
Group type: COMPARATOR
Intervention: BSE-018 in the fasted state (treatment A)
Number of subjects: 0
Study 11441425 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0.5, 1, and 2 mg/70 kg)
Number of subjects: 15
Study 11441425 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2.5, 5, and 10 mg/70 kg)
Number of subjects: 15
Study 11441425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (2.5, 5, and 10 mg/70 kg)
Number of subjects: 15
Study 11441425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (7.5 and 15 mg/70 kg)
Number of subjects: 15
Study 11441425 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 9883777 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational tools (multimedia course modules)
Number of subjects: 164
Study 9075778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 350 mg/m2 as intravenous bolus injection plus folinic acid (FA) 200 mg/m2 and interferon 5 x 10(6) U/m2 (regimen A)
Number of subjects: 76
Study 9075778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500 mg/m2 as 2-hour infusion plus folinic acid (FA) 200 mg/m2 and interferon 5 x 10(6) U/m2 (regimen B)
Number of subjects: 76
Study 16296710 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily, adjusted to 10 mg after 2 weeks if necessary)
Number of subjects: 0
Study 16296710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7019407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxacillin plus sisomicin and carbenicillin (treatment group)
Number of subjects: 24
Study 7019407 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin alone (control group)
Number of subjects: 24
Study 30378465 — intervention group
Group type: COMPARATOR
Intervention: High-dose caffeine (10 mg/kg)
Number of subjects: 12
Study 30378465 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose caffeine (4 mg/kg)
Number of subjects: 12
Study 30378465 — intervention group
Group type: COMPARATOR
Intervention: Repeated-dose caffeine (2 mg/kg before each match to a total of 10 mg/kg)
Number of subjects: 12
Study 30378465 — intervention group
Group type: COMPARATOR
Intervention: Selective caffeine administration (6.16 ± 1.58 mg/kg)
Number of subjects: 12
Study 30202508 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic intervention using the robot 'CommU'
Number of subjects: 68
Study 30202508 — intervention group
Group type: COMPARATOR
Intervention: Human agent intervention
Number of subjects: 68
Study 26152757 — intervention group
Group type: EXPERIMENTAL
Intervention: Central BP intervention (CBP)
Number of subjects: 286
Study 26152757 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 286
Study 23797624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg/kg added to 2% lidocaine
Number of subjects: 40
Study 23797624 — intervention group
Group type: COMPARATOR
Intervention: 2% Lidocaine (Control)
Number of subjects: 40
Study 22465650 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 80
Study 22465650 — intervention group
Group type: COMPARATOR
Intervention: Glidescope
Number of subjects: 80
Study 20565999 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein, carbohydrate-free (HP-0C; 30, 0 and 70 En%)
Number of subjects: 45
Study 20565999 — intervention group
Group type: COMPARATOR
Intervention: High protein (HP; 30, 40 and 30 En%)
Number of subjects: 45
Study 20565999 — intervention group
Group type: COMPARATOR
Intervention: Normal protein (NP; 10, 60 and 30 En%)
Number of subjects: 45
Study 20565999 — intervention group
Group type: COMPARATOR
Intervention: Normal protein, glycogen-lowering exercise (NP-g; 10, 60 and 30 En%)
Number of subjects: 45
Study 20565999 — intervention group
Group type: COMPARATOR
Intervention: High protein (HP) vs Normal protein (NP)
Number of subjects: 45
Study 20565999 — intervention group
Group type: COMPARATOR
Intervention: High protein, carbohydrate-free (HP-0C) vs High protein (HP)
Number of subjects: 45
Study 20565999 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein, carbohydrate-free (HP-0C) vs Normal protein (NP-g)
Number of subjects: 45
Study 17629719 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuGDNF via continuous bilateral intraputaminal infusion
Number of subjects: 34
Study 16140442 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal incision closed with Z-plasties
Number of subjects: 0
Study 16140442 — intervention group
Group type: COMPARATOR
Intervention: Modified Bruner incision closed by Y-V plasties
Number of subjects: 0
Study 12805964 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinfamide treatment (4.3 g/kg dose) administered at 3- or 6-month intervals.
Number of subjects: 302
Study 9764615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg every 4 hours)
Number of subjects: 206
Study 9764615 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg every 4 hours)
Number of subjects: 206
Study 9764615 — intervention group
Group type: COMPARATOR
Intervention: Oral and Vaginal misoprostol
Number of subjects: 206
Study 8181333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide added to albuterol sulfate
Number of subjects: 20
Study 8181333 — intervention group
Group type: COMPARATOR
Intervention: Albuterol alone
Number of subjects: 20
Study 8181333 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study 8181333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide in open study
Number of subjects: 20
Study 3372885 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Structured Clinical Examination (OSCE)
Number of subjects: 0
Study 30393104 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) at doses of 50 mg, 75 mg, and 100 mg, with training (reviewed IFU and shown how to inject)
Number of subjects: 123
Study 30393104 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE) at doses of 50 mg, 75 mg, and 100 mg, without training (only given IFU)
Number of subjects: 123
Study 27167852 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured protocol model
Number of subjects: 1252
Study 27167852 — intervention group
Group type: COMPARATOR
Intervention: Clinical acumen model
Number of subjects: 1252
Study 24781225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 192
Study 24781225 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with antidepressants and antipsychotics
Number of subjects: 192
Study 22835841 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction treatment in three contexts (BCD)
Number of subjects: 68
Study 22835841 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction treatment in one context (B)
Number of subjects: 68
Study 22835841 — intervention group
Group type: COMPARATOR
Intervention: Control group (same context as extinction)
Number of subjects: 68
Study 20555288 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + Testosterone (40 mg testosterone undecanoate)
Number of subjects: 50
Study 20555288 — intervention group
Group type: COMPARATOR
Intervention: Estrogen + Placebo
Number of subjects: 50
Study 20555288 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + Testosterone
Number of subjects: 50
Study 18482290 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg daily for 1 year)
Number of subjects: 225
Study 18482290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15933240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (fruit and vegetable consumption, multivitamin intake, red meat consumption, physical activity)
Number of subjects: 0
Study 15933240 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 14750614 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg once daily for 5 days)
Number of subjects: 593
Study 14750614 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 10 days)
Number of subjects: 593
Study 14750614 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 593
Study 14750614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 593
Study 10501246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccine composed of native outer membrane vesicles (NOMV)
Number of subjects: 32
Study 8689808 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg
Number of subjects: 12
Study 8689808 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice
Number of subjects: 12
Study 8689808 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 1326012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 0
Study 1326012 — intervention group
Group type: COMPARATOR
Intervention: Foscarnet
Number of subjects: 0
Study 6731753 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjuvac (dialysed aqueous extract of pollens chemically conjugated to activated sodium alginate)
Number of subjects: 40
Study 6731753 — intervention group
Group type: COMPARATOR
Intervention: Allpyral (pyridine-extracted alum-precipitated crude extract)
Number of subjects: 40
Study 30366115 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Tubal Occlusion (PTO)
Number of subjects: 165
Study 30366115 — intervention group
Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 165
Study 28590525 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U abobotulinumtoxinA
Number of subjects: 258
Study 28590525 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 U abobotulinumtoxinA
Number of subjects: 258
Study 28590525 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 U abobotulinumtoxinA
Number of subjects: 258
Study 28590525 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated injections of abobotulinumtoxinA
Number of subjects: 258
Study 27039205 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine with ≤15% alcohol content twice a day for 3-4 weeks
Number of subjects: 141
Study 27039205 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplement (such as Boost® or Ensure®)
Number of subjects: 141
Study 27039205 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine with ≤15% alcohol content
Number of subjects: 141
Study 24413342 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) treatment
Number of subjects: 81
Study 24413342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness treatment
Number of subjects: 81
Study 21805588 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG patterns indicating LAD occlusion
Number of subjects: 3602
Study 21805588 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG patterns indicating RCA and LCx involvement
Number of subjects: 3602
Study 21805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Study threshold for ST-segment elevation
Number of subjects: 3602
Study 21805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal ST-segment depression prevalence
Number of subjects: 3602
Study 21805588 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB cases
Number of subjects: 3602
Study 21805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Left main coronary occlusions
Number of subjects: 3602
Study 21122516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral plus enema mesalazine treatment (PINCE)
Number of subjects: 0
Study 21122516 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalazine treatment alone (Control)
Number of subjects: 0
Study 17381912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers exchangeable for fruit juice
Number of subjects: 190
Study 17381912 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 190
Study 17381912 — intervention group
Group type: COMPARATOR
Intervention: Advice group (midwives' advice and leaflets)
Number of subjects: 190
Study 16269638 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus thermal stimulation (TS) for 30 minutes daily for 6 weeks
Number of subjects: 46
Study 16269638 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation treatment
Number of subjects: 46
Study 16269638 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus thermal stimulation (TS)
Number of subjects: 46
Study 12412828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of mycophenolate mofetil alone (treatment 1)
Number of subjects: 6
Study 12412828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of mycophenolate mofetil and 2400 mg of calcium polycarbophil (treatment 2)
Number of subjects: 6
Study 12412828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of mycophenolate mofetil and 2400 mg of calcium polycarbophil with 30 mg of lansoprazole for 5 days (treatment 3)
Number of subjects: 6
Study 9706948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1.25 mg/kg)
Number of subjects: 10
Study 9706948 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (1 mg/kg)
Number of subjects: 10
Study 9706948 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.125 mg/kg)
Number of subjects: 10
Study 9706948 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 7596854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous lead system
Number of subjects: 48
Study 2120201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40
Study 2120201 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 40
Study 312297 — intervention group
Group type: EXPERIMENTAL
Intervention: salsalate (salicylsalicylic acid) 3000 mg
Number of subjects: 20
Study 312297 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin 3900 mg
Number of subjects: 20
Study 312297 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30730896 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA-related stress group (n = 45)
Number of subjects: 86
Study 30730896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 28422463 — intervention group
Group type: COMPARATOR
Intervention: Manual Toothbrush (MTB) alone
Number of subjects: 290
Study 28422463 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush (MTB) plus String Floss (SF)
Number of subjects: 290
Study 28422463 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush (MTB) plus Philips Sonicare AirflossPro with Cool Mint Listerine® Antiseptic (AFPL)
Number of subjects: 290
Study 28422463 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush (MTB) plus Philips Sonicare AirflossPro with BreathRx™ (AFPB)
Number of subjects: 290
Study 25139195 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 20
Study 25139195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23305980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 9
Study 23305980 — intervention group
Group type: COMPARATOR
Intervention: Intermittent normoxic training (INT)
Number of subjects: 9
Study 21628399 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 555
Study 21628399 — intervention group
Group type: COMPARATOR
Intervention: Crossover cohort (switching from deferoxamine to deferasirox)
Number of subjects: 555
Study 19337257 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemical faecal occult blood testing (FIT) at cut-off 75 ng/ml
Number of subjects: 10011
Study 19337257 — intervention group
Group type: COMPARATOR
Intervention: Guaiac-based faecal occult blood test (gFOBT)
Number of subjects: 10011
Study 19337257 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemical faecal occult blood testing (FIT) at varying cut-off levels (50-200 ng/ml)
Number of subjects: 10011
Study 16234288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg pegylated interferon alpha‐2b
Number of subjects: 16
Study 16234288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg pegylated interferon alpha‐2b
Number of subjects: 16
Study 15273177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguards
Number of subjects: 301
Study 15273177 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 301
Study 15273177 — intervention group
Group type: COMPARATOR
Intervention: Non-users of headgear
Number of subjects: 301
Study 15273177 — intervention group
Group type: COMPARATOR
Intervention: Non-users of mouthguards
Number of subjects: 301
Study 11125531 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 0
Study 11125531 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational practice
Number of subjects: 0
Study 11125531 — intervention group
Group type: COMPARATOR
Intervention: No practice
Number of subjects: 0
Study 9314346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 9314346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8323338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms/day
Number of subjects: 19
Study 8323338 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 micrograms/day
Number of subjects: 19
Study 8323338 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 800 micrograms/day
Number of subjects: 19
Study 8323338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wash out periods)
Number of subjects: 19
Study 3521767 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen, 40 mg daily for three years
Number of subjects: 179
Study 3521767 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 179
Study 30307466 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks
Number of subjects: 106